Nutex Health Inc.

NASDAQ•NUTX

CEO: Dr. Thomas T. Vo M.B.A., M.D.

Sector: Healthcare

Industry: Medical - Healthcare Information Services

Listing Date: 2022-04-04

Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.

Contact Information

6030 South Rice Avenue, Suite C, Houston, TX, 77081, United States

713-660-0557

www.nutexhealth.com

Market Cap

$666.29M

P/E (TTM)

6.6

53.3

Dividend Yield

52W High

$193.07

52W Low

$40.67

52W Range

47%

Rank47Top 61.9%

3.4

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 3.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$267.80M+239.88%

4-Quarter Trend

EPS

$8.27-580.81%

4-Quarter Trend

FCF

$99.21M+1507.37%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Soars 239% Total revenue reached $267.8M for Q3 2025, up 239.3% from $78.8M in Q3 2024, driven by IDR success.

Swing to Net Income Net income attributable to stockholders was $55.4M in Q3 2025, reversing prior year's $8.8M net loss for the quarter.

Adjusted EBITDA Jumps Adjusted EBITDA increased to $98.5M in Q3 2025, up 917.5% compared to $9.7M in the comparable prior period.

Cash Position Strengthened Cash and equivalents grew substantially to $166.0M as of September 30, 2025, up from $40.6M at year-end 2024.

Risk Factors

Stock-Based Compensation Spikes Nine-month stock-based compensation expense hit $119.6M, a $117.7M increase, tied to ramping hospital obligations.

Potential Share Dilution Disputes over earn-out formulas could require issuing up to 1.36M shares, representing 19.7% of current outstanding stock.

Ongoing Legal Challenges Securities class action and derivative lawsuits filed; outcomes are uncertain and could materially affect financial position.

Arbitration Expense Costs Total arbitration costs reached $116.2M for nine months, reflecting significant third-party vendor fees for dispute resolution.

Outlook

Hospital Facility Expansion Expect opening three new hospital facilities by end of 2025, supporting clinical services expansion plans.

IPA Growth Strategy Plan launching one to three additional Independent Physician Associations annually, focusing on geographic expansion near micro-hospitals.

Future Financing Needs Seeking larger financing commitments to supplement smaller lines of credit; subject to favorable market conditions.

Convertible Note Conversion Remaining unsecured convertible notes converted $4.9M principal plus interest in October 2025, reducing future debt obligations.

Peer Comparison

Revenue (TTM)

AMN

$2.73B

-8.5%

EVH

$1.88B

-26.6%

NUTX

$981.20M

+236.0%

Gross Margin (Latest Quarter)

ARCT

408.3%

-19.5pp

DNA

124.4%

-21.7pp

CTMX

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
DAWN	$1.03B	-9.7	-23.4%	0.5%
CDNA	$966.93M	-45.0	-6.5%	4.8%
BFLY	$929.58M	-12.1	-35.3%	6.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

1.3%

Moderate Growth

4Q Net Income CAGR

-3.5%

Stable Profitability

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:Mar 5, 2026

EPS:$5.56

Revenue:$258.82M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data